{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:21:08Z","timestamp":1771305668174,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00108-022-01335-7","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T14:04:47Z","timestamp":1656511487000},"page":"736-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gerinnungsdiagnostik im klinischen Alltag \u2013\u00a0Teil\u00a02","Coagulation diagnostics in the clinical routine\u2014part\u00a02"],"prefix":"10.1007","volume":"63","author":[{"given":"Michael","family":"Metze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Platz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pfrepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirak","family":"Petros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"1335_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1046\/j.1537-2995.1999.39199116895.x","volume":"39","author":"D Murray","year":"1999","unstructured":"Murray\u00a0D, Pennell\u00a0B, Olson\u00a0J (1999) Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion 39:56\u201362","journal-title":"Transfusion"},{"key":"1335_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11239-018-1643-0","volume":"45","author":"A Rottenstreich","year":"2018","unstructured":"Rottenstreich\u00a0A, Zacks\u00a0N, Kleinstern\u00a0G et al (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J\u00a0Thromb Thrombolysis 45:543\u2013549","journal-title":"J Thromb Thrombolysis"},{"key":"1335_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/FTD.0000000000000594","volume":"41","author":"E Wieland","year":"2019","unstructured":"Wieland\u00a0E, Shipkova\u00a0M (2019) Pharmacokinetic and pharmacodynamic drug monitoring of direct-acting oral anticoagulants: where do we stand? Ther Drug Monit 41:180\u2013191","journal-title":"Ther Drug Monit"},{"key":"1335_CR4","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1111\/jth.13486","volume":"14","author":"S Testa","year":"2016","unstructured":"Testa\u00a0S, Legnani\u00a0C, Tripodi\u00a0A et\u00a0al (2016) Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a\u00a0multicenter\/multiplatform study. J\u00a0Thromb Haemost 14:2194\u20132201","journal-title":"J Thromb Haemost"},{"key":"1335_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1160\/TH13-10-0871","volume":"111","author":"SJ Francart","year":"2014","unstructured":"Francart\u00a0SJ, Hawes\u00a0EM, Deal\u00a0AM et al (2014) Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 111:1133\u20131140","journal-title":"Thromb Haemost"},{"key":"1335_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ijlh.12528","volume":"38","author":"R Gosselin","year":"2016","unstructured":"Gosselin\u00a0R, Grant\u00a0RP, Adcock\u00a0DM (2016) Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 38:505\u2013513","journal-title":"Int J Lab Hematol"},{"key":"1335_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","volume":"118","author":"RC Gosselin","year":"2018","unstructured":"Gosselin\u00a0RC, Adcock\u00a0DM, Bates\u00a0SM et\u00a0al (2018) International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 118:437\u2013450","journal-title":"Thromb Haemost"},{"key":"1335_CR8","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood-2018-04-791541","volume":"132","author":"JM Connors","year":"2018","unstructured":"Connors\u00a0JM (2018) Testing and monitoring direct oral anticoagulants. Blood 132:2009\u20132015","journal-title":"Blood"},{"key":"1335_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jth.13227","volume":"14","author":"JH Levy","year":"2016","unstructured":"Levy\u00a0JH, Ageno\u00a0W, Chan\u00a0NC et\u00a0al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J\u00a0Thromb Haemost 14:623\u2013627","journal-title":"J Thromb Haemost"},{"key":"1335_CR10","first-page":"462","volume":"16","author":"A Tripodi","year":"2018","unstructured":"Tripodi\u00a0A, Ageno\u00a0W, Ciaccio\u00a0M et\u00a0al (2018) Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIbioC and SIPmeL. Blood Transfus 16:462\u2013470","journal-title":"Blood Transfus"},{"key":"1335_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jth.13912","volume":"16","author":"J Douxfils","year":"2018","unstructured":"Douxfils\u00a0J, Ageno\u00a0W, Samama\u00a0CM et\u00a0al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a\u00a0practical guide for clinicians. J\u00a0Thromb Haemost 16:209\u2013219","journal-title":"J Thromb Haemost"},{"key":"1335_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12959-016-0084-2","volume":"14","author":"L Brunetti","year":"2016","unstructured":"Brunetti\u00a0L, Sanchez-Catanese\u00a0B, Kagan\u00a0L et al (2016) Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thromb\u00a0J 14:10","journal-title":"Thromb J"},{"key":"1335_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1160\/TH11-06-0391","volume":"107","author":"MM Samama","year":"2012","unstructured":"Samama\u00a0MM, Contant\u00a0G, Spiro\u00a0TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379\u2013387","journal-title":"Thromb Haemost"},{"key":"1335_CR14","first-page":"e48","volume":"43","author":"J Evrard","year":"2021","unstructured":"Evrard\u00a0J, Hardy\u00a0M, Dogne\u00a0JM et al (2021) Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. Int J Lab Hematol 43:e48\u2013e51","journal-title":"Int J Lab Hematol"},{"key":"1335_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1160\/TH13-03-0202","volume":"110","author":"J Douxfils","year":"2013","unstructured":"Douxfils\u00a0J, Dogne\u00a0JM, Mullier\u00a0F et al (2013) Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 110:543\u2013549","journal-title":"Thromb Haemost"},{"issue":"6","key":"1335_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ijlh.13618","volume":"43","author":"M Metze","year":"2021","unstructured":"Metze\u00a0M, Kloter\u00a0T, Stobe\u00a0S et\u00a0al (2021) Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants. Int J Lab Hematol 43(6):1539\u20131548. https:\/\/doi.org\/10.1111\/ijlh.13618","journal-title":"Int J Lab Hematol"},{"key":"1335_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","volume":"69","author":"LH Lam","year":"1976","unstructured":"Lam\u00a0LH, Silbert\u00a0JE, Rosenberg\u00a0RD (1976) The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570\u2013577","journal-title":"Biochem Biophys Res Commun"},{"key":"1335_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1056\/NEJM197208172870703","volume":"287","author":"D Basu","year":"1972","unstructured":"Basu\u00a0D, Gallus\u00a0A, Hirsh\u00a0J et\u00a0al (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N\u00a0Engl J Med 287:324\u2013327","journal-title":"N Engl J Med"},{"key":"1335_CR19","first-page":"253","volume":"43","author":"RA Marlar","year":"2017","unstructured":"Marlar\u00a0RA, Clement\u00a0B, Gausman\u00a0J (2017) Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 43:253\u2013260","journal-title":"Semin Thromb Hemost"},{"key":"1335_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12185-014-1702-z","volume":"101","author":"M Mitsuguro","year":"2015","unstructured":"Mitsuguro\u00a0M, Okamoto\u00a0A, Shironouchi\u00a0Y et al (2015) Effects of factor VIII levels on the APTT and anti-Xa activity under a\u00a0therapeutic dose of heparin. Int J Hematol 101:119\u2013125","journal-title":"Int J Hematol"},{"key":"1335_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.thromres.2019.01.002","volume":"175","author":"D Ratano","year":"2019","unstructured":"Ratano\u00a0D, Alberio\u00a0L, Delodder\u00a0F et al (2019) Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thromb Res 175:53\u201358","journal-title":"Thromb Res"},{"key":"1335_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13054-021-03554-0","volume":"25","author":"R Descamps","year":"2021","unstructured":"Descamps\u00a0R, Moussa\u00a0MD, Besnier\u00a0E et al (2021) Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a\u00a0multicenter cohort study. Crit Care 25:127","journal-title":"Crit Care"},{"key":"1335_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1345\/aph.1Q161","volume":"45","author":"DJ Guervil","year":"2011","unstructured":"Guervil\u00a0DJ, Rosenberg\u00a0AF, Winterstein\u00a0AG et\u00a0al (2011) Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45:861\u2013868","journal-title":"Ann Pharmacother"},{"key":"1335_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","volume":"119","author":"RA Raschke","year":"1993","unstructured":"Raschke\u00a0RA, Reilly\u00a0BM, Guidry\u00a0JR et al (1993) The weight-based heparin dosing nomogram compared with a\u00a0\u201cstandard care\u201d nomogram. A randomized controlled trial. Ann Intern Med 119:874\u2013881","journal-title":"Ann Intern Med"},{"key":"1335_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11606-010-1551-2","volume":"26","author":"AN Hurewitz","year":"2011","unstructured":"Hurewitz\u00a0AN, Khan\u00a0SU, Groth\u00a0ML et\u00a0al (2011) Dosing of unfractionated heparin in obese patients with venous thromboembolism. J\u00a0Gen Intern Med 26:487\u2013491","journal-title":"J Gen Intern Med"},{"key":"1335_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/oby.20029","volume":"21","author":"SX Joncas","year":"2013","unstructured":"Joncas\u00a0SX, Poirier\u00a0P, Ardilouze\u00a0JL et\u00a0al (2013) Delayed efficient anticoagulation with heparin in patients with a\u00a0weight of 110\u202fkg and more treated for acute coronary syndrome. Obesity (Silver Spring) 21:1753\u20131758","journal-title":"Obesity (Silver Spring)"},{"key":"1335_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/2229-5151.119200","volume":"3","author":"AT Gerlach","year":"2013","unstructured":"Gerlach\u00a0AT, Folino\u00a0J, Morris\u00a0BN et al (2013) Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients. Int J Crit Illn Inj Sci 3:195\u2013199","journal-title":"Int J Crit Illn Inj Sci"},{"key":"1335_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1345\/aph.1P088","volume":"44","author":"JN Riney","year":"2010","unstructured":"Riney\u00a0JN, Hollands\u00a0JM, Smith\u00a0JR et\u00a0al (2010) Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother 44:1141\u20131151","journal-title":"Ann Pharmacother"},{"key":"1335_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/MBC.0000000000000336","volume":"26","author":"S Shin","year":"2015","unstructured":"Shin\u00a0S, Harthan\u00a0EF (2015) Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a\u00a0retrospective chart review. Blood Coagul Fibrinolysis 26:655\u2013660","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1335_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/20009666.2018.1466599","volume":"8","author":"J Durrani","year":"2018","unstructured":"Durrani\u00a0J, Malik\u00a0F, Ali\u00a0N et\u00a0al (2018) To be or not to be a\u00a0case of heparin resistance. J\u00a0Community Hosp Intern Med Perspect 8:145\u2013148","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"1335_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000203747","volume":"4","author":"E Schwarz","year":"1950","unstructured":"Schwarz\u00a0E, Usteri\u00a0C, Koller\u00a0F (1950) Heparin tolerance and heparin hypersensitivity. Acta Haematol 4:148\u2013157","journal-title":"Acta Haematol"},{"key":"1335_CR32","doi-asserted-by":"publisher","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","volume":"126","author":"J Hirsh","year":"2004","unstructured":"Hirsh\u00a0J, Raschke\u00a0R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S\u2013203S","journal-title":"Chest"},{"key":"1335_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1053\/j.jvca.2004.01.013","volume":"18","author":"JH Levy","year":"2004","unstructured":"Levy\u00a0JH (2004) Heparin resistance and antithrombin: should it still be called heparin resistance? J\u00a0Cardiothorac Vasc Anesth 18:129\u2013130","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1335_CR34","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jama.1966.03100180108036","volume":"196","author":"PG Hattersley","year":"1966","unstructured":"Hattersley\u00a0PG (1966) Activated coagulation time of whole blood. JAMA 196:436\u2013440","journal-title":"JAMA"},{"key":"1335_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1538-7836.2005.01672.x","volume":"4","author":"R Al Dieri","year":"2006","unstructured":"Al Dieri\u00a0R, Alban\u00a0S, Beguin\u00a0S et al (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J\u00a0Thromb Haemost 4:83\u201389","journal-title":"J Thromb Haemost"},{"key":"1335_CR36","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1161\/01.CIR.86.5.1370","volume":"86","author":"C Kroon","year":"1992","unstructured":"Kroon\u00a0C, ten Hove\u00a0WR, de Boer\u00a0A et al (1992) Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500\u202fIU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86:1370\u20131375","journal-title":"Circulation"},{"key":"1335_CR37","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","volume":"2","author":"DM Witt","year":"2018","unstructured":"Witt\u00a0DM, Nieuwlaat\u00a0R, Clark\u00a0NP et\u00a0al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2:3257\u20133291","journal-title":"Blood Adv"},{"key":"1335_CR38","volume-title":"Fachinformation Mono-Embolex","author":"Pharma A","year":"2021","unstructured":"Fachinformation Mono-Embolex Stand 2021"},{"key":"1335_CR39","unstructured":"Fachinformation Clexane Stand 2020"},{"key":"1335_CR40","volume-title":"Fachinformation Fragmin","author":"Pharma P","year":"2021","unstructured":"Fachinformation Fragmin Stand 2021"},{"key":"1335_CR41","volume-title":"Fachinformation innohep","author":"Pharma L","year":"2021","unstructured":"Fachinformation innohep Stand 2021"},{"key":"1335_CR42","volume-title":"Fachinformation Arixtra","author":"Pharma A","year":"2021","unstructured":"Fachinformation Arixtra Stand 2021"},{"key":"1335_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0049-3848(00)00412-6","volume":"101","author":"JS Barrett","year":"2001","unstructured":"Barrett\u00a0JS, Hainer\u00a0JW, Kornhauser\u00a0DM et\u00a0al (2001) Anticoagulant pharmacodynamics of tinzaparin following 175 iu\/kg subcutaneous administration to healthy volunteers. Thromb Res 101:243\u2013254","journal-title":"Thromb Res"},{"key":"1335_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00228-015-1880-5","volume":"71","author":"F Atiq","year":"2015","unstructured":"Atiq\u00a0F, van den Bemt\u00a0PM, Leebeek\u00a0FW et al (2015) A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol 71:921\u2013929","journal-title":"Eur J Clin Pharmacol"},{"key":"1335_CR45","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker\u00a0A, Arepally\u00a0GM, Chong\u00a0BH et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360\u20133392","journal-title":"Blood Adv"},{"key":"1335_CR46","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge\u00a0D, Frere\u00a0C, Connors\u00a0JM et\u00a0al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20:e566\u2013e581","journal-title":"Lancet Oncol"},{"key":"1335_CR47","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s11239-012-0773-z","volume":"34","author":"Y Yukizawa","year":"2012","unstructured":"Yukizawa\u00a0Y, Inaba\u00a0Y, Watanabe\u00a0S et\u00a0al (2012) Plasma accumulation of fondaparinux 2.5\u202fmg in patients after total hip arthroplasty. J\u00a0Thromb Thrombolysis 34:526\u2013532","journal-title":"J Thromb Thrombolysis"},{"key":"1335_CR48","volume-title":"Fachinformation Argatra","author":"Pharma MT","year":"2021","unstructured":"Fachinformation Argatra Stand 2021"},{"key":"1335_CR49","volume-title":"Fachinformation Orgaran","author":"Pharma A","year":"2021","unstructured":"Fachinformation Orgaran Stand 2021"},{"key":"1335_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/cc4975","volume":"10","author":"M Levi","year":"2006","unstructured":"Levi\u00a0M, Opal\u00a0SM (2006) Coagulation abnormalities in critically ill patients. Crit Care 10:222","journal-title":"Crit Care"},{"key":"1335_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0039-1683416","volume":"39","author":"R Kohli","year":"2019","unstructured":"Kohli\u00a0R, Chaturvedi\u00a0S (2019) Epidemiology and clinical manifestations of immune thrombocytopenia. Hamostaseologie 39:238\u2013249","journal-title":"Hamostaseologie"},{"key":"1335_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/asheducation-2010.1.135","volume":"2010","author":"A Greinacher","year":"2010","unstructured":"Greinacher\u00a0A, Selleng\u00a0K (2010) Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010:135\u2013143","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1335_CR53","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMp068309","volume":"356","author":"TE Warkentin","year":"2007","unstructured":"Warkentin\u00a0TE (2007) Drug-induced immune-mediated thrombocytopenia\u2014from purpura to thrombosis. N\u00a0Engl J Med 356:891\u2013893","journal-title":"N Engl J Med"},{"key":"1335_CR54","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","volume":"120","author":"A Cuker","year":"2012","unstructured":"Cuker\u00a0A, Gimotty\u00a0PA, Crowther\u00a0MA et al (2012) Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a\u00a0systematic review and meta-analysis. Blood 120:4160\u20134167","journal-title":"Blood"},{"key":"1335_CR55","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","volume":"131","author":"C Kearon","year":"2018","unstructured":"Kearon\u00a0C, Parpia\u00a0S, Spencer\u00a0FA et\u00a0al (2018) Antiphospholipid antibodies and recurrent thrombosis after a\u00a0first unprovoked venous thromboembolism. Blood 131:2151\u20132160","journal-title":"Blood"},{"key":"1335_CR56","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1182\/blood-2008-10-184879","volume":"113","author":"WM Lijfering","year":"2009","unstructured":"Lijfering\u00a0WM, Brouwer\u00a0JL, Veeger\u00a0NJ et\u00a0al (2009) Selective testing for thrombophilia in patients with first venous thrombosis: results from a\u00a0retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 113:5314\u20135322","journal-title":"Blood"},{"key":"1335_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.2009.08022.x","volume":"149","author":"T Baglin","year":"2010","unstructured":"Baglin\u00a0T, Gray\u00a0E, Greaves\u00a0M et\u00a0al (2010) Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 149:209\u2013220","journal-title":"Br J Haematol"},{"key":"1335_CR58","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMra1700365","volume":"377","author":"JM Connors","year":"2017","unstructured":"Connors\u00a0JM (2017) Thrombophilia testing and venous thrombosis. N\u00a0Engl J Med 377:1177\u20131187","journal-title":"N Engl J Med"},{"key":"1335_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides\u00a0SV, Meyer\u00a0G, Becattini\u00a0C et\u00a0al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart\u00a0J 41:543\u2013603","journal-title":"Eur Heart J"},{"key":"1335_CR60","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/j.1538-7836.2008.03055.x","volume":"6","author":"M Coppens","year":"2008","unstructured":"Coppens\u00a0M, Reijnders\u00a0JH, Middeldorp\u00a0S et\u00a0al (2008) Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J\u00a0Thromb Haemost 6:1474\u20131477","journal-title":"J Thromb Haemost"},{"key":"1335_CR61","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1182\/blood-2014-03-559757","volume":"124","author":"F Couturaud","year":"2014","unstructured":"Couturaud\u00a0F, Leroyer\u00a0C, Tromeur\u00a0C et\u00a0al (2014) Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood 124:2124\u20132130","journal-title":"Blood"},{"key":"1335_CR62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11239-015-1316-1","volume":"41","author":"SM Stevens","year":"2016","unstructured":"Stevens\u00a0SM, Woller\u00a0SC, Bauer\u00a0KA et\u00a0al (2016) Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J\u00a0Thromb Thrombolysis 41:154\u2013164","journal-title":"J Thromb Thrombolysis"},{"key":"1335_CR63","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3324\/haematol.10516","volume":"92","author":"P Prandoni","year":"2007","unstructured":"Prandoni\u00a0P, Noventa\u00a0F, Ghirarduzzi\u00a0A et\u00a0al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626\u00a0patients. Haematologica 92:199\u2013205","journal-title":"Haematologica"},{"key":"1335_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/ijlh.13342","volume":"43","author":"R Siriez","year":"2021","unstructured":"Siriez\u00a0R, Dogne\u00a0JM, Gosselin\u00a0R et\u00a0al (2021) Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 43:7\u201320","journal-title":"Int J Lab Hematol"},{"key":"1335_CR65","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia\u00a0D, Erkan\u00a0D (2018) Diagnosis and management of the antiphospholipid syndrome. N\u00a0Engl J Med 378:2010\u20132021","journal-title":"N Engl J Med"},{"key":"1335_CR66","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo\u00a0V, Denas\u00a0G, Zoppellaro\u00a0G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365\u20131371","journal-title":"Blood"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01335-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T16:04:33Z","timestamp":1656518673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01335-7"}},"subtitle":["\u00dcberwachung von Antikoagulanzientherapien, neu aufgetretene Thrombozytopenie und Thrombophilie","Monitoring of anticoagulation treatment, new-onset thrombocytopenia and thrombophilia"],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01335-7","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"5 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M. Metze<\/b>: A. Finanzielle Interessen: Forschungsf\u00f6rderung: Daiichi Sankyo. \u2013\u00a0Referentenhonorar: Bayer, Pfizer.\u00a0\u2013 Berater: Bayer, Boehringer Ingelheim, Daiichi Sankyo. \u2013\u00a0B. Nichtfinanzielle Interessen: Angestellter Kardiologe und H\u00e4mostaseologe, Universit\u00e4tsklinikum Leipzig | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung (DGK), Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung (GTH), International Society on Thrombosis and Haemostasis (ISTH). <b>M. Platz<\/b>: A. Finanzielle Interessen: M. Platz gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Facharzt, Klinik und Poliklinik f\u00fcr Kardiologie, Universit\u00e4tsklinikum Leipzig | Mitgliedschaften: Berufsverband Deutscher Internistinnen und Internisten (BDI), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), DGK, European Society of Cardiology (ESC), Marburger Bund. <b>S. Petros<\/b>: A. Finanzielle Interessen: Forschungsf\u00f6rderung: Bayer Vital, CSL Behring, Stago, Werfen. \u2013\u00a0Vortragshonorar: Bristol Myers Squibb, Boehringer Ingelheim, CSL Behring, MSD, Novo Nordisk, Portola, Sanofi, Sch\u00f6chl Medical.\u00a0\u2013 B. Nichtfinanzielle Interessen: Leiter der Interdisziplin\u00e4ren Internistischen Intensivmedizin, Universit\u00e4tsklinikum Leipzig, Leiter des Bereichs H\u00e4mostaseologie, Universit\u00e4tsklinikum Leipzig | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche Gesellschaft f\u00fcr Internistische Intensivmedizin und Notfallmedizin (DGIIN), Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Intensiv- und Notfallmedizin (DIVI), GTH, European Society of Intensive Care Medicine (ESICM), ISTH. <b>C.\u00a0Pfrepper<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar: Bayer, Pfizer \u2013\u00a0Berater: Pfizer\u00a0\u2013 Forschungsf\u00f6rderung: Leo Pharma, Roche\/Chugai, Zacros\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter H\u00e4mostaseologe, Universit\u00e4tsklinikum Leipzig | Mitgliedschaften: GTH, ISTH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}